23. Sakushima, K., Takeda, H, & Aoi, Y. (2021, December). Orphan drug designation and development in Japan: 25 years of experience and assessment. Nature Reviews, 20, 893–894. https://media.nature.com/original/magazine-assets/d41573- 021-00045-3/d41573-021-00045-3.pdf 24. Armstrong, A. (2025, March 5). Rare disease biotechs left in a lurch as Congress fails to renew priority review program. BioSpace. https://www.biospace.com/business/rare-disease-biotechs-left-in-a-lurch-as-congress-fails-to-renew-priority- review-program#:~:text=Congress%20did%20not%20reauthorize%20the,than%20it%20did%20in%202024 25. National Organization for Rare Disorders. (2024). Hope for millions of children living with rare diseases. https://rarediseases.org/wp-content/uploads/2024/07/NORD-PRV-One-Pager.pdf 26. Deutscher Bundestag. (2024). Incentivising the development of new antibacterial treatments 2024. https://www.bundestag.de/resource/blob/1032556/9f57f6dca89cafeaa83e82b3398c2ec1/20_14-1_0112_TOP-3_Dr- Ralf-Sudbrak_g7progress_.pdf 27. National Institutes of Health Office of Research on Women’s Health. (2024). History of women’s inclusion in clinical research. https://orwh.od.nih.gov/toolkit/recruitment/history 28. Steinberg, J. R., Turner, B. E., Weeks, B. T., Magnani, C. J., Wong, B. O., Rodriguez, F., Yee, L. M., & Cullen, M. R. (2021, June 18). Analysis of female enrollment and participant sex by burden of disease in U.S. clinical trials between 2000 and 2020. JAMA Network Open, 4(6), e2113749. https://doi.org/10.1001/jamanetworkopen.2021.13749 29. Bierer, B. E., Meloney, L. G., Ahmed, H. R., & White, S. A. (2022). Advancing the inclusion of underrepresented women in clinical research. Cell Reports Medicine, 3(4), 100553. https://doi.org/10.1016/j.xcrm.2022.100553 30. Vitale, C., Fini, M., Spoletini, I., Lainscak, M., Seferovic, P ., & Rosano, G. M. C. (2017, April 1). Under-representation of elderly and women in clinical trials. International Journal of Cardiology, 232, 216–221. https://doi.org/10.1016/j. ijcard.2017.01.018 31. Innovative Medicines Initiative. (n.d.). Background. IMI ConcePTION. Retrieved April 4, 2025 from https://www.imi- conception.eu/background/ 32. David, A. L., Ahmadzia, H., Ashcroft, R., Bucci-Rechtweg, C., Spencer, R. N., & Thornton, S. (2022, July 25). Improving development of drug treatments for pregnant women and the fetus. Therapeutic Innovation & Regulatory Science, 56(6), 976–990. https://doi.org/10.1007/s43441-022-00433-w 33. Novartis. (2021, February 16). Novartis Entresto granted expanded indication for chronic heart failure by FDA. Novartis. https://www.novartis.com/news/media-releases/novartis-entresto-granted-expanded-indication-chronic-heart-failure-fda 34. Bevan, M., Burrone, V., & Graham, L. (2020, Fall). Pediatric drug development: Trends and perspectives in the United States. Evidera. https://www.evidera.com/wp-content/uploads/2020/10/A07_PediatricDrugDev_EFFall20.pdf 35. European Medicines Agency. (n.d.). Paediatric regulation. Retrieved April 4, 2025, from https://www.ema.europa.eu/en/ human-regulatory-overview/paediatric-medicines-overview/paediatric-regulation 36. European Medicines Agency. (n.d.). Paediatric investigation plans. Retrieved April 4, 2025, from https://www.ema. europa.eu/en/human-regulatory-overview/research-development/paediatric-medicines-research-development/paediatric- investigation-plans 37. U.S. Food and Drug Administration. (2024, June). Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies: Guidance for industry. https://www.fda.gov/media/179593/download 38. National Academies of Sciences, Engineering, and Medicine. (2023). Exploring the role of the Food and Drug Administration in regulating women’s health research: Proceedings of a workshop. The National Academies Press. https://nap.nationalacademies.org/catalog/27595/advancing-clinical-research-with-pregnant-and-lactating-populations- overcoming-real 39. U.S. Food and Drug Administration. (2024, June). Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies: Guidance for industry. https://www.fda.gov/media/179593/download 40. U.S. Food and Drug Administration. (2021). Study of sex differences in the clinical evaluations medical products: Guidance for industry. https://www.fda.gov/media/184907/download 41. 2024 Access to Medicine Foundation. (2024). 2024 Access to medicine index. https://accesstomedicinefoundation.org/ sectors-and-research/index-ranking 42. European Medicines Agency. (2011). Introduction to EuroMediSAFE. https://www.euromedicat.eu/research/euromedisafe 43. World Economic Forum in collaboration with the McKinsey Health Institute. (2025). Blueprint to close the women’s health gap: How to improve lives and economies for all. https://reports.weforum.org/docs/WEF_Blueprint_to_Close_the_ Women%E2%80%99s_Health_Gap_2025.pdf 44. Aggarwal, N. R., Patel, H. N., Mehta, L. S., Sanghani, R. M., Lundberg, G. P ., Lewis, S. J., Mendelson, M. A., Wood, M. J., Volgman, A. S., & Mieres, J. H. (2018). Sex differences in ischemic heart disease: Advances, obstacles, and next steps. Circulation: Cardiovascular Quality and Outcomes, 11(2), e004437. https://doi.org/10.1161/ circoutcomes.117.004437 45. Martinkova, J., Quevenco, F., Karcher, H., et al. (2021). Proportion of women and reporting of outcomes by sex in clinical trials for Alzheimer disease: A systematic review and meta-analysis. JAMA Network Open, 4(9), e2124124. https://doi. org/10.1001/jamanetworkopen.2021.24124 Prescription for Change: Policy Recommendations for Women’s Health Research 26

Prescription for Change 2025